The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.

Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.

Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Elias Jabbour, MD, discusses frontline treatment considerations in newly diagnosed acute lymphocytic leukemia.

Isatuximab plus initial VRd and Rd maintenance demonstrated deep responses and MRD negativity in transplant-ineligible newly diagnosed multiple myeloma.

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

The therapeutic arsenal for patients with ALL in the first line and beyond is expanding beyond traditional approaches, enabling better outcomes for patients.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

ALLO-316, a CD70-directed CAR T-cell therapy, demonstrated preliminary efficacy and safety in CD70-positive ccRCC.

Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

Dr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma.

RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.

NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.

Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

Elias Jabbour, MD, discusses the role of bosutinib as a standard treatment for patients with CML that is resistant or intolerant to prior TKI therapy.

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

Bora Lim, MD, discusses the significance of the FDA approval of adjuvant ribociclib for patients with HR-positive, HER2-negative breast cancer.

Chad Tang, MD, discusses the potential role for radiation therapy in advanced renal cell carcinoma.

Bora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.

Tapotoclax showed manageable safety, and it reduced bone marrow blasts and transfusion dependence in MDS after HMAs.

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Guillermo Garcia-Manero, MD, discusses the relationship between hemoglobin levels and QOL in patients with lower-risk myelodysplastic syndromes.